Methods of identifying compounds that modulate IL-4 receptor-mediated IgE synthesis utilizing a B-cell associated protein
View Patent ↗The present provides compounds capable of modulating IL-4 receptor-mediated IgE production, as well as IL-4 induced processes associated therewith, methods and kits for identifying such compounds that utilize a BAP-37 as a surrogate analyte and methods of using the compounds in a variety of in vitro, in vitro and ex vivo contexts.
1. A method of identifying a compound that modulates IL-4 receptor-mediated IgE production, comprising determining whether the compound binds a B-cell associated protein-37 (BAP 37), wherein the ability to bind the BAP-37 identifies the compound as being a modulator of IL-4 induced IgE production.
2. The method of claim 1 in which the compound identified inhibits IL-4 receptor-mediated IgE production.
3. The method of claim 1 in which the compound identified inhibits IL-4 receptor-mediated isotype switching of B-cells.
4. The method of claim 1 in which the compound identified inhibits IL-4 induced transcription of a germline ε promoter.
5. The method of claim 1 in which the compound specifically modulates IL-4 induced IgE production without significantly modulating production of another Ig isotype.
6. The method of claim 1 in which the BAP-37 is a mammalian BAP-37.
7. The method of claim 6 in which the mammalian BAP-37 is a human BAP-37.
8. The method of claim 1 in which it is determined whether the compound binds the BAP-37 in a competitive binding assay.
9. The method of claim 8 in which the compound competes for binding the BAP-37 with an active CL08 compound.
10. The method of claim 9 in which the active CL08 compound is selected from the group consisting of CL08wt (SEQ ID NO:1), CL08NR (SEQ ID NO: 2), CL08VH (SEQ ID NO:3), and a peptide analog thereof in which one or more of the amide linkages are replaced with an isostere of an amide.
11. The method of claim 1 which is carried out in a cell-free system with an isolated BAP-37.
12. The method of claim 1 in which the compound is a small organic compound.
13. The method of claim 12 in which the small organic compound has a molecular weight in the range of about 100–2500 dalton.
14. The method of claim 1 in which the compound is selected from the group consisting of peptides and peptide isosteres.
15. The method of claim 1 , further including the step of confirming that the identified compound modulates IL-4 induced IgE production.
16. A method of identifying compounds that modulate IL-4 receptor-mediated IgE production, comprising the step of contacting a compound from a pool of candidate compounds with a B-cell associated protein-37 (BAP 37) and identifying those compounds of the pool that bind the BAP-37, thereby identifying those compounds of the pool that modulate IL-4 receptor-mediated IgE production.
17. The method of claim 16 which is carried out in the presence of a compound known to bind the BAP-37 such that those compounds of the pool that competitively bind the BAP-37 are identified.
18. The method of claim 17 in which the compound known to bind the BAP-37 is an active CL08 compound.
19. The method of claim 18 in which the active CL08 compound is selected from the group consisting of CL08wt (SEQ ID NO:1), CL08NR (SEQ ID NO:2), CL08VH (SEQ ID NO:3), and a peptide analog thereof in which one or more of the amide linkages are replaced with an isostere of an amide.
20. The method of claim 16 in which the candidate compounds are peptides or small organic compounds.
21. The method of claim 20 in which the pool of candidate compounds is a phage display library.
22. The method of claim 20 in which the candidate compounds are immobilized on a substrate or a plurality of substrates.
23. The method of claim 16 in which the compound or BAP-37 is labeled with a detectable label.
24. The method of claim 16 in which the BAP-37 is immobilized on a substrate.
25. A kit for identifying compounds that modulate IL-4 induced IgE production, comprising (i) an active CL08 compound, and (ii) a B-cell associated protein-37 (BAP 37) or a cell expressing a BAP-37.
26. The kit of claim 25 in which the active CL08 compound is selected from the group consisting of CL08wt (SEQ ID NO: 1), CL08NR (SEQ ID NO: 2), CL08VH (SEQ ID NO: 3), CL08EL (SEQ ID NO: 4), CL08HY (SEQ ID NO: 5), and a peptide analog thereof in which one or more of the amide linkages are replaced with an isostere of an amide.
27. A method of inhibiting germline ε transcription in a cell, comprising contacting the cell in vitro with an effective amount of an active CL08 compound.
28. The method of claim 27 in which the active CL08 compound is selected from the group consisting of CL08wt (SEQ ID NO: 1), CL08NR (SEQ ID NO: 2), CL08VH (SEQ ID NO: 3), CL08EL (SEQ ID NO: 4), CL08HY (SEQ ID NO: 5), and a peptide analog thereof in which one or more of the amide linkages are replaced with an isostere of an amide.
29. The method according to any one of claim 1 , claim 16 , and claim 27 , in which the BAP-37 is a polypeptide having the amino acid sequence of SEQ ID NO:12.